English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Praziquantel can develop resistance and cannot counteract schistosomiasis pathology. β-glucanwas used as an immunomodulator for innate and acquired immunity. This study evaluated theeffects of β-glucan either alone or with PZQ on chronic Schistosoma mansoni infection. Micewere divided into five groups: uninfected control, infected untreated, PZQ treated, β-glucantreated and combined treatment groups. Treatment started at the end of 8th week P.I. Parasitological,histopathological, immunohistochemical (α-SMA) studies and biochemical assays (Myeloperoxidaseactivity, NO, TNF-α, INF-γ, IL-13 & hydroxyproline) in liver tissues were done.Combination of β-glucan and PZQ therapy resulted in significant decrease in adults count, hepaticegg loads, granuloma number and diameter as well as significant improvement of hepaticpathology and reduction of hepatic fibrosis.

SYNERGY BETWEEN BETA-1, 3-GLUCAN AND PRAZIQUANTEL IN THE TREATMENT OF EXPERIMENTAL CHRONIC SCHISTOSOMIASIS MANSONI